

**DISCLOSURE OF TRANSFERS OF VALUE FROM PHARMACEUTICAL COMPANIES TO HEALTHCARE PROFESSIONALS AND HEALTHCARE ORGANISATIONS**

Publication Date:

*Article 2 - Section 2.03*

|  | Full Name<br><br><i>(Art. 1.01)</i>  | HCPs: City of Principal Practice<br>HCOs: city where registered<br><br><i>(Art. 3)</i> | Country of Principal Practice<br><br><i>(Schedule 1)</i> | Principal Practice Address<br><br><i>(Art. 3)</i> | Unique country local identifier<br>OPTIONAL<br><br><i>(Art. 3)</i> | Donations and Grants to HCOs<br><br><i>(Art. 3.01.1.a)</i> | Contribution to costs of Events<br><i>(Art. 3.01.1.b &amp; 3.01.2.a)</i>              |                   |                       | Fee for service and consultancy<br><i>(Art. 3.01.1.c &amp; 3.01.2.c)</i> |  | Transfers of Value re Research & Development as defined<br><br><i>(Art. 3.04)</i> |     |
|--|--|--|--|---|--|--|---|-------------------|-----------------------|--|--|---|-----|
|  |  |  |  |   |  |  | Sponsorship agreements with HCOs / third parties appointed by HCOs to manage an Event | Registration Fees | Travel & Accomodation | Fees   | Related expenses agreed in the fee for service or consultancy contract |   |     |
| <b>HCPs</b>  | <i>INDIVIDUAL NAMED DISCLOSURE - one line per HCP (i.e. all transfers of value during a year for an individual HCP will be summed up; itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)</i> |  |  |   |  |  |   |                   |                       |  |  |   |     |
|  | Henrik Lindman   | Uppsala  | Sweden   | Kanslikskrivargatan 20                            |  | N/A  | N/A   | N/A               |                       |  | 52462 SEK  |   |     |
|  | <i>OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons</i>  |  |  |   |  |  |   |                   |                       |  |  |   |     |
|  | <b>Aggregate amount attributable to transfers of value to such Recipients - Art. 3.2</b>   |  |  |   |  |  | N/A   | N/A               | N/A                   |  |  |   | N/A |
|  | <b>Number of Recipients (named list, where appropriate) - Art. 3.2</b>   |  |  |   |  |  | N/A   | N/A               | N/A                   |  |  | 1   | N/A |
| <b>% of total transfers of value to individual HCPs - Art. 3.2</b> |  |  |  |   |  | N/A  | N/A   | N/A               |                       |  | 100%   | N/A   |     |
| <b>HCOs</b>  | <i>INDIVIDUAL NAMED DISCLOSURE - one line per HCO (i.e. all transfers of value during a year for an individual HCO will be summed up; itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)</i> |  |  |   |  |  |   |                   |                       |  |  |   |     |
|  | EAS European Atherosclerosis Society   |  | Sweden   | Mässansgata 10, 412 51 Goeteborg                  | -  | -  | 2 627421 SEK  | -                 | -                     | -  | -  | N/A   |     |
|  | <i>OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons</i>  |  |  |   |  |  |   |                   |                       |  |  |   |     |
|  | <b>Aggregate amount attributable to transfers of value to such Recipients - Art. 3.2</b>   |  |  |   |  |  | -   | -                 | -                     | -  | -  | -   | N/A |
|  | <b>Number of Recipients (named list, where appropriate) - Art. 3.2</b>   |  |  |   |  |  | -   | -                 | -                     | -  | -  | -   | N/A |
| <b>% of total transfers of value to individual HCOs - Art. 3.2</b> |  |  |  |   |  | -  | -   | -                 | -                     | -  | -  | N/A   |     |
| <b>R&amp;D</b>   | <b>AGGREGATE DISCLOSURE</b>  |  |  |   |  |  |   |                   |                       |  |  |   |     |
|  |  |  |  |   |  |  |   |                   |                       |  |  |   |     |